ANTICOAGULANT PEPTIDYL-ARGININE ALDEHYDE DERIVATIVES

Abstract: The invention relates to new peptidyl-arginine aldehyde derivatives of general formula (I): Q-D-Xaa-Pro-Arg-H, wherein Q represents an acyl group of formula Q'-O-CO-, where Q' represents an alkyl group with 1-3 carbon atoms, D-Xaa represents 3-cyclobutyl-D-alanyl- or 3-cyclo-pentyl-D-alanyl- group, Pro stands for L-prolyl- group, and Arg stands for L-arginyl- group, and acid-addition salts thereof formed with an organic or inorganic acid and pharmaceutical compositions containing the same. The compounds of formula (I) have valuable therapeutic, particularly anticoagulant, properties together with inhibiting platelet functions and thrombosis development.

Description: ANTICOAGULANT PEPTTDYL-ARGININE ALDEHYDE DERIVATTVES Thi s invention relates to new peptidyl-arginine aldehyde derivatives of general formula (I) , Q-D-Xaa-Pro-Arg-H (I) where in Q represents an acyl group of formula Q'-O-CO-, wherein Q' represents an a l kyl group with 1 -3 carbon atoms, D-Xaa represents a 3-cyclobutyl-D-alanyl or 3-cycl opentyl-D-alanyl group, Pro stands for an L-prolyl residue, and Arg stands for an L-arginyl residue, and their acid-addition salts formed with an organic or inorgan ic acids and pharmaceutica l compositions con¬ taining the same . The new compounds of general formula (I) have valuable therapeutic, particularly anticoagulant, anti- platelet and antithrombotic properties. Particularly preferred representatives of the com- pounds of general formu la (I) of the invention are the following derivatives: ethoxycarbonyl-3-cyclobutyl-D-alanyl-L-prolyl-L-arginine aldehyde, methoxycarbonyl-3-cyclobutyl-D-alanyl-L-prolyl-L-arginine aldehyde, ethoxycarbonyl-3-cyclopentyl-D-alanyl-L-prolyl-L-arginine aldehyde, methoxycarbonyl-3-cyclopentyl-D-alanyl-L-prolyl-L-argi- nine aldehyde, and their acid-addition salts with organic and inorganic acids, preferably the hemisulfate salts. Definitions The abbreviations of the amino acids, their substi¬ tuents and peptides built up therefrom are in accordance with the prior art, e. g. Biochem. J. 126, 773 (1972); Bio¬ chemistry 14, 449 (1975). Amino acids: Arg = L-arginine [(2R)-2-amino-5-guanidino-pentanoic acid], Asp = L-aspartic acid [(2S)-2-amino-3-carboxypropionic acid], boroArg = L-boroarginine [(1 R)-1 -amino-4-guanidino- butylboric acid], D-Cba = 3-cyclobutyl-D-alanine [(2R)-2-amino-3-cyclo- butylpropionic acid], DL-Cbg = DL-cyclobutyl-glycine [(2RS)-2-amino-2- cyclobutylacetic acid], D-Chg = D-2-cyclohexyl-glycιne [(2R)-2-amιno-cyclohexyl- acetic acid], D-Cpa = 3-cyclopentyl-D-alanιne [(2R)-2-amιno-3-cyclo- pentylpropionic acid], Gla = gamma-carboxy-L-glutamic acid [(2S)-2-amιno-4,4- dicarboxybutyric acid], Glu = L-glutamic acid [(2S)-2-amιno-4-carboxybutyπc GIp = L-pyroglutamic acid [(5S)-2-pyrrolιdone-5-carboxylιc Gly = glycine (2-amιnoacetιc acid), D-MePhe = N-methyl-3-phenyl-D-alanιne [(2R)-2-methyl- amιno-3-phenylpropιonιc acid], D-MePhg = D-N-methyl-phenylglycine [(2R)-2-amιno-2- phenylacetic acid], Nal(1) = 3-(naphth-1-yl)-L-alanιne [(2S)-2-amιno-3- (naphth-1 -yl)-propιonιc acid], D-Phe = 3-phenyl-D-alanιne [(2R)-2-amιno-3-phenyl- propionic acid], Pro = L-proline [(2S)-pyrrolιdιne-2-carboxylιc acid] Substituents Ac = acetyl, Boc = t-butoxycarbonyl, Bz = benzoyl, Eoc = ethoxycarbonyl, Et = ethyl, iPoc = isopropoxy- carbonyl, Me = methyl, 4MeP = 4-methyl-pentanoyl, Moc = methoxycarbonyl, pNA = p-nitrophenylamino, Poc = propoxycarbonyl, Tos = p-toluene-sulfonyl, Z = benzyloxycarbonyl Peptides and derivatives The abbreviations of ammo acids alone represent the respective L-ammo acid. The D-amino acid is marked separately, i e. 3-phenyl-D-alanιne = D-Phe The hyphen before and after the amino acid abbreviation designates a missing hydrogen atom from the amino group or a missing hydroxy group from the carboxy group, resp Accordingly, Eoc-D-Cba-Pro-Arg-H represents ethoxy- carbonyl-3-cyclobutyl-D-alanyl-L-prolyl-L-argιnιne alde¬ hyde, while Bz-lle-Glu-Gly-Arg-pNA represents benzoyl-L- isoleucyl-L-glutamyl-glycyl-L-arginine p-nitroanihde Description of the known art Blood clotting represents part of the protective mech¬ anism in the organism Induced by a vessel wall injury a blood clot is formed to prevent bleeding to death In ad- dition, vascular diseases, haemostasis and pathological activation of clotting factors may also induce blood clot¬ ting In this case the vessel is obstructed fully or partially by the intravascular thrombus formed and thrombosis de¬ velops Fibπnolysis represents an other part of the prot- ective mechanism Here excess blood clots are removed by the enzymes participating in thrombolysis and the dis¬ solution of the thrombus, too The blood clotting process is a cascade reaction, a series of catalysed enzyme reactions, where plasma pro- teins, the so-called clotting factors, are activated conse¬ cutively The factors are marked by Roman numerals, the active form is represented by the letter "a" Trivial names are in use too, thus fibrinogen = factor I (fl), fibrin = factor la (fla), prothrombin = factor II (fll) and thrombin = factor lla (f lla) Serine proteases (fXlla, fVlla, fXIa, fIXa fXa, fXa and thrombin), some accelerating co-factors (fVa and f V Ilia) and the clottable molecule itself (fibrin) are all formed during the clotting process fXa and thrombin are the last two factors among the proteases formed Thrombin, formed upon the action of fXa, initiates the fission of fib-πnogen, resulting in the fibrin clot According to the earlier concept of blood clotting mechanism [R G MacFariane Nature 202 498 (1964), E W Davie and 0 D Ratnoff Science 145 1310 (1964)] fX is activated in two ways by an intrinsic and an extrinsic pathway In the former case the process is initiated by the surface-activated fXII (fXlla) with the transformation fXI→fXIa which is followed by the reaction fIX→flXa, fX is activated by fIXa In the extrinsic pathway the process is initiated by the appearance of the cellular surface receptor, the tissue factor (TF) and the development of the [fVII+TF] or [fVlla + TF] complex fX is activated by the [fVlla+TF] complex According to recent findings blood clotting in the living organism is a result of both pathways combined [E W Davie et al , Biochemistry 43 10363 (1991)] where the main steps are the following 1 In the case of vessel wall injury or disease, TF migrates to the surface and binds a portion of factor VII circulating in the blood The [fVII+TF]-complex formed is converted by the action of suitable trace amounts of pro¬ teases (fXlla, fXa, fIXa and thrombin) into the active en¬ zyme complex [fVlla + TF] which activates a small portion of plasma factors IX and X (i e small amounts of fIXa and fXa are formed), then it is inactivated by the action of TFPI (Tissue Factor Pathway Inhibitor, earlier name Lipo- protem-Associated Coagulation Inhibitor), the common inhibitor of both fXa and [fVlla+TF] [T J Girard et al , Nature 338, 518-520 (1989)] 2 The fIXa generated together with factor X and co- factor Villa produces, in the presence of Ca *+ ions, on a phospholipid surface (PL) the "tenase" complex, [flXa+fVllla + fX + PL + Ca + + ], wherein fX is activated to fXa 3 The fXa generated up to this point, together with prothrombin (fll) and cofactor Va, produces the "prothrom- binase complex" [fXa+fVa+fll + PL + Ca * + ], which has a structure similar to that of "tenase" Inside this complex prothrombin is converted to thrombin The fV→fVa and fVI 11 — >fVI 11 a conversions can be performed either by fXa or thrombin 4 The small amount of thrombin generated converts a portion of fXI to the enzyme fXIa and activates some fac¬ tors VIII and V, to produce further amounts of fVllla and fVa, resp By now fXIa can carry out the conversion of factor IX to the enzyme fIXa With this step the chain re- action starting with the Xase-complex and terminated with thrombin formation is resumed With the repetition of the process increasing amounts of thrombin are formed. 5 At a suitable high thrombin concentration the fib- πnogen dissolved in the plasma undergoes partial proteo- lysis, a fibrin-monomer is generated which is first asso¬ ciated to a soluble fibrin polymer, then it is converted to insoluble fibrin polymer Here also the thrombin is playing a role, as fXllla, the factor performing polymerisation, is produced upon its action [L Lorand and K Konishi, Arch Biochem Biophys 105, 58 (1964) The insoluble fibrin polymer is the main component of the blood clot and thrombus, the other being the blood platelet aggregate which is generated primarily upon the action of thrombin, too The thrombus or blood clot formed entraps the major part of thrombin generated during the process which triggers a new coagulation process when it gets into the solution during the dissolution of the throm- bus [A K Gash et al , Am J Cardiol 57, 175 (1986), R Kumar et al , Thromb Haemost 72, 713 (1994)] The above features demonstrate the key role of throm¬ bin in thrombus formation Consequently all compounds interfering with the function and/or formation of thrombin are of major importance in the therapy of thrombosis At present the most widely and successfully used compounds applied for the prophylaxis and treatment of thrombosis are the heparins and the vitamin K antagonist coumaπns (e g Syncumar and Warfarin) which are in¬ direct thrombin inhibitors Hepaπn catalyses the reaction between thrombin and its natural inhibitor, antithrombin-lll (AT- 111). However, this action of hepaπn is absent if the plasma concen¬ tration of AT- 111 is lower than 75 % of the normal level [R Egbring et al , Thromb Haemost 42, 225 (1979)] It is also of importance that the thrombin bound by the above- mentioned thrombus fails to be inhibited by this indirect mechanism as it is inaccessible to the hepaπn-AT-lll- complex [J I Weitz et al , J Clin Invest 86, 385 (1990)] In addition, side effects such as treatment-related haem¬ orrhages and thromboembolisms developing due to immu- nopathological processes are not negligible either [J M Walenga et al , Clin Appl Thrombosis/Haemostasis, 2(Suppl.1) S21-S27 (1996)] The vitamin K antagonists may be administered orally, too, their effect is developing after 16-24 hours They in¬ hibit the development of the reactive forms of some Gla- containmg clotting factors (I e prothrombin) To achieve therapeutic effects partial inhibition (60-70 %) is required [M P Esnouf and C V Prowse, Biochim Biophys Acta 490, 471 (1977)] which can be attained by suitable drug dosage Vitamin K antagonists, however, are dif-ficult to use due to their narrow therapeutic range, strong dependence on diet composition (vitamin K) and variable individual sensitivity The first highly potent synthetic compound directly inhibiting thrombin was the tripeptide aldehyde D-Phe- Pro-Arg-H, a reversible inhibitor, exhibiting significant anticoagulant activity both in vitro and in vivo [S Bajusz et al , in Peptides Chemistry, Structure and Biology (R Walter and J Meienhofer, Eds ), Ann Arbor Publ , Ann Arbor, Michigan, USA, 603-608 (1975), Int J Peptide Protein Res 12, 217 (1978)] A series of compounds re- lated to D-Phe-Pro-Arg-H have been synthesised One of the first was Boc-D-Phe-Pro-Arg-H [S Bajusz et al , Int J Peptide Protein Res 12, 217 (1978)] and the chloro- methylketone analogue (D-Phe-Pro-Arg-CH 2 CI) which proved to be an irreversible inhibitor [C Kettner and E Shaw, Thromb Res 14, 969 (1979)] Further peptides and acylpeptides to be mentioned are the boroarginine ana¬ logues (D-Phe- and Boc-D-Phe- as well as Ac-D-Phe-Pro- -boroArg) which are potent reversible thrombin inhibitors [C Kettner et al , J Biol Chem 265 18289 (1990)] and other analogues of Boc-D-Phe-Pro-Arg-H including the Boc-D-Chg-Pro-Arg-H analogue [(P D Gesellchen and R T Shuman, European patent specification No 0,479,489 A2 (1992)] In aqueous solutions D-Phe-Pro-Arg-H is prone to undergo spontaneous conversion but D-MePhe-Pro-Arg-H (GYKI-14766), obtained by methylating the terminal ammo group, proved to be of suitable stability while retaining the activity of the parent compound [S Bajusz et al , U S patent specification No 4,703036 (1987), J Med Chem 33, 1729 (1990)] Blood clotting and thrombus formation were significantly inhibited in laboratory animals by the compound [D Bagdy et al , Thromb Haemost 67, 357 and 68, 125 (1992), J V Jackson et al , J Pharm Exp Ther 261, 546 (1992)], its inhibitory action on the enzymes of fibπnolysis was negligible, co-administered with thrombo- lytics it significantly promoted the dissolution of the thrombus [C V Jackson et al , J Cardiovascular Phar- macol 21, 587 (1993)] which could not be attained with the hepaπn-AT-lll complex Several compounds related to D-MePhe-Pro-Arg-H have been synthesised, e g D- -MePhg-Pro-Arg-H [R T Shuman et al , J Med Chem 36, 314 (1993)] Anticoagulant activity (i e inhibition of the proteo¬ lytic reactions in the process) is measured by anticoag¬ ulant tests, e g in the thrombin time (TT), activated partial thromboplastin time (APTT) and prothrombin time (PT) tests [E J W Bovie et al , Mayo Clinic Laboratory Manual of Haemostasis, W B Saunders Co , Philadelphia (1971)] Plasma, inhibited in spontaneous coagulation, e g citrate-plasma, is made to coagulate and the re¬ quired coagulation time is measured Upon the action of anticoagulants the coagulation time is prolonged propor- tionally to the inhibition of the reactιon(s) in the process The anticoagulant effect can be characterised by the sub¬ stance concentration required to prolong the coagulation time twofold compared to the control (IC 5 o) The effect of anticoagulants on individual coagulant proteases is mea- sured by the amidolytic method [R Lottenberg et al , Methods in Enzymol. 80, 341 (1981); G. Cleason, Blood Coagulation and Fibrinolysis 5, 411 (1994)]. The isolated active factor (e. g. thrombin, fXa) and its chromogen or fluorogen peptide-amide substrate are reacted in the pres¬ ence or absence of the inhibitor, resp. The enzyme inhib¬ iting action is characterised by the inhibitory constant (IC 5 o) measured during amidolysis. In the TT test coagulation is initiated by the thrombin added to the citrate plasma. In the system 22 pmol/ml of thrombin is functioning and its inhibition can be measured on the fibrinogen (one of the natural substrates of throm¬ bin) in the presence of plasma components. In the APTT and PT tests the full coagulation process takes place. Depending on the activator fX is activated either by the extrinsic or the intrinsic pathway. The generated fXa activates prothrombin to thrombin which, in turn, triggers plasma coagulation. The coagulation time is prolonged if the enzymes or one of them is inhibited by the inhibitor. In the APTT and PT tests at most 40 pmol/ml Xa can be generated (this is the full amount of factor X present in both systems) while 150 pmol/ml (APTT) and 350 pmol/ml (PT) of thrombin are generated [B. Kaiser et al., Thromb Res. 65, 157 (1992)]. In the case of D-MePhe-Pro-Arg-H (C1) the concen¬ tration prolonging clotting time twofold in the TT, APTT and PT tests amounted to 87, 622 and 2915 nM, resp. These values and the amount of thrombin (22, 150 and 350 pmol/ml) functioning in the tests increased similarly, suggesting that C1 behaves as a thrombin inhibitor in both the APTT and the PT tests and has only slight or no m- fluence on the operation of fXa In good agreement with these results the amidolytic effect of thrombin on Tos-Gly- -Pro-Arg-pNA substrate is inhibited by C1 with an IC 5 o = 2 nM value, while the amidolytic effect of fXa on the cor¬ responding Bz-lle-Glu-Gly-Arg-pNA substrate was only slightly affected with an IC 50 = 9,1 mM value (Bajusz et al unpublished results) It is an inherent characteristic of the blood clotting mechanism that the process is inhibited not only by direct thrombin inhibitors but also by factors hindering thrombin formation, e g fXa inhibitors The 60-member polypeptide isolated from tick, TAP (Tick Anticoagulant Peptide) [L Waksman et al , Science 248, 593 (1990), A B Kelly et al , Circulation 86, 1411 (1992)] and DX-9065a (C2), a synthetic non-peptide, ( + )-(2S)-2-[4[[(3S)-1 -acetιmιdoyl-3- pyrrol id ιnyl]oxy]phenyl]-3-[7[amιdιno-2-naphthyl]-prop ionic acid hydrochloride pentahydrate [T Hara et al , Thromb Haemost 71, 314 (1994), T Yokoya a et al , Circulation 92, 485 (1995)] are strong inhibitors of blood clotting and thrombus formation Both the amidolytic effect of fXa and plasma clotting are strongly inhibited in the PT and APTT tests by these compounds, i e both the free and the com¬ plex-bound Xa factors are equally well inhibited while ac¬ cording to their nature as specific fXa inhibitors thrombin is not inhibited at all, i e they fail to exert any activity in the TT test 4-MeP-Asp-Pro-Arg-H (03) (international patent application No. 93/15756) and Boc-D-Phe-Nal(1 )- Arg-H (04) (international patent application No. 95/13693) are synthetic peptide inhibitors of fXa According to the literature 03 and 04 inhibit the amidolytic activity of fXa on the Z-D-Arg-Gly-Arg-pNA substrate at IC 5 o = 57 and 30 nM, resp No data are available on their anticoagulant potency In our own tests 03 and 04 exhibited also significant inhibition on the Bz- Me-Glu-Gly-Arg-pNA substrate while their anticoagulant activity proved to be negligible in the plasma clotting tests The published (02) and measured (C3-C4) activities of synthetic fXa inhibitors compared to the antithrombin compound 01 are presented in Table 1 The data of Table 1 demonstrate that in the case of 01 the anticoagulant effect is due to the inhibition of thrombin while in the case of 02 to the inhibition of fXa The signi- ficant fXa inhibitory effect of 03 and 04 is not accom¬ panied by any significant anticoagulant effect Most prob¬ ably the fXa active centre in the prothrombmase complex is inaccessible to 03 and 04, these peptides can inhibit only free fXa in solution Table 1 fXa inhibiting (A) and anticoagulant (B) effect of known synthetic inhibitors A: B: IC 50 , μ a Inhibitor IC 50 , n ιM b PT APTT TT C1 9133 2.91 0.62 0.09 C2 70 0.52 0.97 NA C C3 64 19.32 4.59 0.87 C4 86 53.62 9.96 17.24 a Peptide concentration prolonging clotting time twofold compared to the control in the prothrombin time (PT), activated partial thromboplastin time (APTT) and thrombin time (TT) test Value measured with isolated human fXa on Bz-lle-Glu-Gly- -Arg-pNA chromogen substrate c NA = inactive According to a recent publication [N. A. Prager et al., Circulation 92, 962 (1995)] not only thrombin but also fac¬ tor Xa, entrapped in the thrombus/blood clot and liberated during dissolution, contributes to the initiation and main¬ tenance of a new coagulation process through the acti- vation of the [fVII + TF]-complex or factors V and VIII, resp. Consequently, it is advantageous if the anticoagu¬ lants are able to inhibit factor Xa in addition to the inhi¬ bition of thrombin, particularly if this inhibition is ex¬ tended to the clot-bound thrombin and factor Xa, too. Short description of the invention It is the objective of the present invention to prepare new peptide derivatives with improved anticoagulant acti- vity compared to known compounds which exhibit anti¬ coagulant activity at oral administration, too. It was observed that the anticoagulant effect of BOC- D-Phe-Pro-Arg-H (C5) in TT and APTT tests is smaller than that of tripeptide aldehyde 01 , but in PT test it is somewhat better, and it inhibits factor Xa with 10 times lower IC 50 than 01. It has been unexpectedly found that the substitution of Eoc-group for BOC-group in 05 posi¬ tively modifies the anticoagulant effect of the peptide, because Eoc-D-Phe-Pro-Arg-H thus obtained shows higher effects than 05 in all three tests; in addition, its activity is higher than that of 01 not only in PT but in APTT test as well, while its fXa inhibiting effect is similar to that of BOC-peptide 05. The anticoagulant effect of Moc-D-Phe- Pro-Arg-H (07) is similar to that of 06 Eoc-compound, but its fXa inhibiting effect is somewhat higher These findings are demonstrated in Table 2. Table 2 Anticoagulation (A) and fXa inhibiting effect (B) of peptide aldehydes with the structure R-D-Phe-Pro-Arg-H Peptide aldehyde A IC so. μM" B No R TT APTT PT IC Sf)> μM b 01 Me 0.09 0 62 2 93 9 13 05 Boc 0.20 0 76 2 27 0 91 06 Eoc 0 13 0 38 1 91 0 92 07 Moc 0 20 0 29 1 96 0 13 a Peptide concentration prolonging clotting time twofold compared to the control b Value measured with isolated human fXa on Bz-lle-Glu-Gly- -Arg-pNA chromogenic substrate It has also been found that even more effective anti- coagulant compounds can be obtained if the N-terminal amino acid is changed from phenylalanine to 3-cyclobutyl- alanine, while when incorporating the homologous cyclobutyl-glycine into the N-terminal position the activity decreases. Apart from 3-cyclobutylalanine, substitution with 3-cyclopentylalanine also gives effective peptidyl- arginine aldehydes. It has also been observed that substitution of methoxycarbonyl or propoxycarbonyl groups for the N-terminal ethoxy-carbonyl group modifies the activity spectrum, i.e. the ratio of the measured activities in the individual tests. Detailed description of the invention This invention relates to new peptide aldehyde deri- vatives of general formula (I), Q-D-Xaa-Pro-Arg-H (I) wherein Q represents an acyl group of formula Q'-O-CO- where Q' is an alkyl group with 1-3 carbon atoms, Xaa represents a 3-cyclobutyl-D-alanyl or 3-cyclo- pentyl-D-alanyl group, Pro stands for an L-prolyl residue, and Arg stands for an L-arginyl residue, and their acid-addition salts formed with an organic or inorganic acid and pharmaceutical compositions con¬ taining the same. The compounds of general formula (I), wherein Q, Q\ Xaa, Pro and Arg have the same meaning as above, are prepared e.g. by condensing an acyldipeptide Q-D-Xaa- -Pro with an L-arginine lactam, protected on the guanidino group with a benzyloxycarbonyl group, and reducing the obtained protected tripeptide lactam to the protected tri- peptide aldehyde of the formula Q-D-Xaa-Pro-Arg(Z)-H, finally removing the Z group from the guanidino group of argi-nine, and isolating the peptide derivative of general for-mula (I) as its addition salt formed with an organic or inorganic acid. The acyl-dipeptide, Q-D-Xaa-Pro, used as starting material, is prepared e.g. by acylating a D-Xaa amino acid with a Q' alkyl ester of chloroformic acid in a basic me¬ dium and the Q-D-Xaa acylamino acid thus obtained is coupled to L-proline. Q-D-Xaa, required for the coupling to proline, can advantageously be prepared by acylating the racemic DL-Xaa compound, converting the DL-acylamino acid to its methyl ester and enzymatically resolving the Q-DL-Xaa- OMe racemic ester. The Q-D-Xaa-OMe thus obtained is then saponified to the needed Q-D-Xaa acylamino acid. The compounds of general formula (I) of the inven- tion, wherein Q, Xaa, Pro and Arg have the same meaning as above, exhibit strong anticoagulant activity both in vitro and in vivo and possess excellent bioavailability. The in vitro anticoagulant effects of the compounds of general formula (I) was measured by the prothrombin time (PT), activated partial thromboplastin time (APTT) and thrombin time (TT) tests [D. Bagdy et al., Thromb. Haemost. 67, 325 (1992)]. The fXa-inhibiting effect of the compounds was also determined using the Bz-lle-Glu-Gly- -Arg-pNA chromogen substrate (see method M6). The results obtained are presented in Table 3. The corresponding data of C1 thrombin inhibitor, C6 Eoc-D- Phe- compound and 08 Eoc-DL-Cba- analogue served as controls. In the Table the compounds are listed in the decreasing order of PT activity. The data definitely de¬ monstrate the beneficial effect of the terminal Cba- and Cpa-moieties compared to the Phe (see 1, 4 and 06 compounds), and e.g. to the homologous cyclobutyl- glycine (see DL-series 08, 09 and C10 compounds). Table 3 Anticoagulant (A) and fXa inhibiting (B) effect of the new peptidyl aldehydes (1 - 4, general formula Q-D-Xaa-Pro-Arg-H) and that of control compounds (C1, C6 and 08 - C10) in the decreasing order of PT activity 3 Q-Xaa-Pro-Arg-H A' IC b0 , μM ' BilCso Exmpl Q Xaa PT APTT TT nM c 2 Moc D-Cba 1.12 0.25 0 11 388 1 Eoc D-Cba 1.15 0.35 0 11 40 4 Eoc D-Cpa 1.41 0.24 0.10 27 3 iPoc D-Cba 1.70 0.60 0.19 36 Control compounds 08 Eoc DL-Cba 1.49 0.50 0 13 68 09 Eoc DL-Cpa 1 90 0.48 0.26 43 06 Eoc D-Phe 1.91 0.38 0.13 917 01 D-MePhe 2.91 0.62 0.09 9133 C10 Eoc DL-Cbg 6.15 0.77 0.88 82 a Peptide concentration inducing twofold thrombin time prolongation compared to control b Identical to Example number describing preparation of the respective compound c Value measured on substrate Bz-lle-Glu-Gly-Arg-pNA with isolated human fXa (See methods M1 - M5) The inhibitory effect of the new compounds of the invention on plasmin (PL) as well as on plasmin formation induced by tissue plasminogen activator (tPA) and uro- kinase (UK) was examined by the fibrin-plate method [D. Bagdy et al.: Thromb. Haemost. 67, 325 (1992)]. Compounds C1 and 05 served as controls. It is well known that the antifibrinolytic effect of 01 proved to be insig¬ nificant in vivo, and it could be used as an adjuvant in dissolving the experimental thrombus, while the anti¬ fibrinolytic activity of 05 was well detectable in vivo [C.V. Jackson et al.: J. Cardiovasc. Pharmacol. 21, 587 (1993)] In Table 4 the results obtained with the new compounds 1 and 2 as well as those with controls 01 and 05 are presented as an example. In addition to the IC 50 values (columns A) the efficacy of the compounds related to 01 are also listed (columns B) The latter data indicate that similarly to compound 01 the antifibrinolytic activity of the new 1 and 2 compounds is moderate; their activity against the three enzymes tested is 3.2 - 4.5 - 39 times lower than that of compound 05. Table 4 The inhibitory effect (IC 50 ) of the new peptidyl-arginine aldehydes of the invention and that of control compounds with similar structure on plasmin (PL) as well as on plasmin formation induced by tissue plasmmogen activator (tPA) and urokmase (UK) studied by the fibrin-plate method* Peptidyl arginine aldehyde A IC 50 and B relative efficiency' (Example) 0 PL tPA UK A B A B A B Eoc-D-Cba-Pro-Arg-H (1) 39 1 4 27 49 120 07 Moc-D-Cba-Pro-Arg-H (2) 235 0 23 92 1 4 153 05 Eoc-D-Cpa-Pro-Arg-H (3) 98 0 55 38 3 5 46 1 8 D-MePhe-Pro-Arg-H (01) 54 1 0 132 1 0 82 1 0 Boc-D-Phe-Pro-Arg-H (05) 12 4 5 6 22 0 3 27 3 " IC 50 = peptide concentration (μM) where the hydrolysed area on the fibrin plate is reduced to 50% compared to the control b Values related to the activity of 01 (1/IC 50 = 1) 0 Identical to the example number describing the preparation of the respective compound The inhibitory effect of the new compounds of general formula (I) on clot-bound fXa and thrombin as well as on fibrin gel-bound thrombin is demonstrated in Table 5 with compounds 1 - 3, the respective values of C1 are used as controls Plasma-clot was obtained by recalcificating platelet-rich human plasma, and fibrin gel by clotting human fibrinogen with human thrombin For the activity measures of fXa and thrombin Z-D-Arg-Gly-Arg- pNA or Tos-Gly-Pro-Arg-pNA substrates were used in agreement with Methods M1-M3 Table 5 Inhibitory effects (IC 50 , μM) of new peptidyl-arginine aldehydes of the invention (1 - 3) and 01 as control compound on clot-bound fXa and thrombin as well as on fibrin-gel bound thrombin 8 Peptidyl-arginine aldehyde Plasma clot Fibrin gel (Number) fXa Thrombin Thrombin Eoc-D-Cba-Pro-Arg-H (1) 0.70 0.39 0.32 Moc-D-Cba-Pro-Arg-H (2) 0.39 0.68 0.64 Eoc-D-Cpa-Pro-Arg-H (3) 0.28 049 0.67 D-MePhe-Pro-Arg-H (01) 1.12 0 38 0.30 8 In determination of IC50 values the activity of fXa and thrombin was measured on Moc-D-Chg-Gly-Arg-pNA or Tos-Gly-Pro-Arg- -pNA substrates according to Methods M2 and M3 b The same as the number of the Example describing the new compound or control (C1) These data show that Eoc-compounds 1 and 3 inhibit not only thrombin but plasma clot-bound fXa, too, with an IC o well below 1 micromole concentration The anticoagulant and platelet aggregation inhibiting effect of the compounds of general formula (I) was studied in New Zealand white rabbits ex vivo according to D Bagdy et al. [Thromb. Haemost 67, 357 (1992)] The com¬ pounds were dissolved in buffered isotonic saline solu- tion and administered i. v (0,04-5 0 mg/kg) or by infusion (0.25-5.0 mg/kg/h) or subcutaπeously (0 5-6 0 mg/kg) or p.o. (2.5-20 mg/kg). The effect of the compounds was de¬ tectable already within 30 minutes following p o. adminis¬ tration, peak values were attained after 60-180 minutes and the therapeutic level was maintained dose-depend- ently for 3->6 hours. The in vivo effect of ethoxycarbonyl-3-cyclobutyl-D- alanyl-L-prolyl-L-arginine aldehyde (1) is presented in detail in Tables 6 and 7 The corresponding values of C1 are listed as controls The compound was administered p o in doses of 5 mg/kg The blood samples drawn from the caudal vein in every 30-60 minutes were analysed The whole blood clotting time (WBCT) and the inhibition of thrombin-induced blood platelet aggregation (PAI) were determined The activated partial thromboplastin time (APTT) and the thrombin time (TT) in the citrate plasma obtained from the blood sample were also measured The APTT and TT values are compiled in Table 6 and the WBCT and PAI values in Table 7 The data of Tables 6 and 7 show that the new com¬ pound 1 has longer-lasting anticoagulant and antiaggre- gation effect than control C1. Table 6 Anticoagulant effect of Eoc-D-Cba-Pro-Arg-H (1) and D-MePhe-Pro- Arg-H (C1) as control in rabbits at p o doses of 5 mg/kg in the APTT and TT tests characterised by relative clotting times 8 Time Eoc-D-Cba -Pro-Arg-H D-MePhe-Pro -Arg-H mm APTT TT APTT TT 0 1 0 1 0 1 0 1 0 30 1 73±047 8 30±567 1 27+0 38 1 52±0 17 45 1 84±0 50 9 04±550 1 30±0 02 250±044 60 1 94±051 9 28±545 1 37±003 475±1 38 90 1 92±0 31 1358±543 1 45±009 1050±4 59 120 1 75±026 16 33±589 1 43±0 11 551 ±3 59 180 1 59±0 12 695±3 73 1 39±009 205±038 240 1 38±008 203±042 1 31±0 11 1 81±039 300 1 28±008 1 77±050 1 25±022 - Ratio of clotting times measured in treated and untreated animals Therapeutic values are in italics Table 7 Anticoagulant and blood platelet aggregation inhibiting (PAI) effect of Eoc-D-Cba-Pro-Arg-H (1) and D-MePhe-Pro-Arg-H (01) in rabbits at p.o doses of 5 mg/kg in the WBCT test characterised by relative clotting time and percentual inhibition* T Tiimmee E Ecoc-D-Cba-P ro-Arg-H (1) D-MePhe-P ro-Arg-H (01) mm. WBCT PAI(%) WBCT PAI(%) 0 1.0 1.0 1.0 1.0 30 1.52±0.22 71.3±16.6 1.07±0.13 52.8±14.7 45 1.58±0.17 55.8±174 1.26±0.07 58.4±15.6 60 1.88±0.45 63.8±21.2 1.55±0.17 54.2111 6 90 1.73±0.33 85.6±10.0 1 61±0.34 83.2± 8.9 120 1.98±0.30 73.6±19 1 1 45±0.21 75.2±12 3 180 1.43±0 13 81.8±11 6 1 44±0.08 47 5±20 9 240 1.12±0.24 594±19.1 1.22±0.08 32.2±16 0 300 1 18±0 08 75 8±11.8 ! Ratio of clotting times measured in treated and untreated animals Therapeutic values are in italics The compounds of the invention of general formula (I) are used for the treatment and prevention of the following diseases where thrombosis and/or hypercoagulability is involved deep venous thrombosis, pulmonary embolism, arterial thrombosis, unstable angina, myocardial infarct, auricular fibrillation and thrombosis-based stroke In atherosclerosis they may be used to prevent diseases of coronary arteries, thrombotic diseases of cerebral ar- teries as surgical prophylaxis of high risk patients, or other surgical prophylaxis They may be applied in the thrombolysis of percutaneous transluminal angioplastics for the prevention of reocclusion, for adjuvant therapy in nephrosis and in diseases with hypercoagulability. in malignant tumours and inflammation (e g arthritis) as well as in diabetes They may be applied in cases where the administration of other anticoagulants fails to be ef- fective or is contramdicated e g lack of antι-thrombιn-1 II in the case of hepaπn or hepaπn-induced thrombocyto- penia (HIT), and e g pregnancy in the case of coumaπns The compounds of the invention and their pharma¬ ceutically acceptable salts are used for therapeutic pur¬ poses alone or preferably in the form of a pharmaceutical formulation The invention also refers to these formula¬ tions The pharmaceutical formulations comprise an ef¬ fective amount of a compound of general formula (I) or a pharmaceutically acceptable salt thereof and known phar¬ maceutically acceptable carriers, filling materials, diluents and/or other pharmaceutical excipients The above carriers, diluents or filling materials can be water, alcohols, gelatine, lactose, saccharose, starch, pectin, magnesium stearate, steaπc acid, talcum, various oils of animal or plant origin, furthermore glycols, e g propylene glycol or polyethylene glycol The pharma- ceutical excipients can be preservatives, various natural or synthetic emulgeators, dispersing or wetting agents, colouring materials, flavouring agents, materials pro¬ moting disintegration and other materials improving the bioavailability of the active ingredient The pharmaceutical compositions of the invention can be prepared in usual formulations, such as oral compo¬ sitions (administered through the mouth, such as tablets, capsules, powders, pills, dragees or granulates) as well as parenteral compositions (drugs administered by avoiding the gastrointestinal system such as injections, infusions, suppositories, plasters or ointments) The therapeutic dose level of the compounds of the invention depends on the individual health status and age of the patient and may vary accordingly, consequently, its level is fixed by the physician designing treatment In dis¬ eases where inhibition of the function and/or formation of thrombin is required for prophylactic or therapeutic pur- poses, a daily oral or parenteral (e g i v ) dose of 0 01 to 1000 mg/kg body weight, preferably 025 to 20 mg/kg body weight, may be administered The compounds of general formula (I) of the invention, administered together with thrombolytic agents (e g tPA or urokinase), actively promote the dissolution of thrombi formed in arteries or veins and efficiently prevent their reformation In such cases it is preferred to administer the compounds of the invention simultaneously with thrombo¬ lytic agents or immediately after thrombolytic treatment The following examples are illustrating but not limiting the scope of the invention The R f values recorded in the examples were deter- mined by thin-layer chromatography using silica gel as adsorbent (DC-Alufolieπ Kieselgel 60 F 25 4 Merck, Darm¬ stadt) in the following developing solvents 1 Ethyl acetate 2 Ethyl acetate - pyridine - acetic acid - water (480206 11) 5 Ethyl acetate - pyridine - acetic acid - water (45206 11) 6 Ethyl acetate - pyridine - acetic acid - water (240206 11) 7 Ethyl acetate - pyridine - acetic acid - water (480 103 55) 9 Ethyl acetate - pyridine - acetic acid - water (120206 11) 13 Ethyl acetate - n-butanol - acetic acid - water (1 1 1 1) The capacity factors (k') specified in the examples were determined with the apparatus "Pharmacia LKB Analytical HPLC System Two" as follows Column "VYDAC C-18 reversed phase 10 mm 300 A, 4 x 250 mm" Buffer A 0 1 % trifluoroacetic acid in water Buffer B 0 1 % trifluoroacetic acid in acetonitrile Gradients applied at 1 ml/mm flow rate I 0-5 mm 0-25 % B, then isocratic 25 % B, II 0-30 mm 0-60 % B Detection of peptide content of the eluates was per¬ formed by UV light at 214 nm Sample concentration was 1 mg/ml buffer A, injection volume 25 μl The gradient applied in the HPLC analysis (I or II) is specified in brackets after the abbreviation at the indi¬ vidual steps of the examples The acylargmme aldehydes are present in equilibrium structures, i e in aldehyde, aldehyde hydrate and two aminocyclol forms During HPLC analysis the aldehyde hydrate and one or both aminocyclol forms appear as se- parate peaks, consequently the acylargmme aldehydes described in the examples are specified by two or three k' values Mass spectrometry The FAB positive lonisation measurements were performed in a Fmnigan MAT 8430 apparatus The samples were dissolved in m-nitrobenzyl- alcohol matrix and introduced directly into the ion source In the spectrum of peptidyl-arginine aldehydes an ad¬ ditional molecule-ion was detectable, that of the addition compound formed with m-nitrobenzyl-alcohol (NBA) [M + H] + and [M + H + NBA] + In the examples the FAB spectral data were specified accordingly The ESI positive lonisation measurements were performed in a VG Quattro (Fisons) apparatus The samples were dissolved in a mixture of acetonitrile - water (1 1) containing 1 % (v/v) of formic acid and were intro¬ duced with a 10 ml sample-loop into the ion source at a flow rate of 15 - 25 ml/mm The specific rotations ([α] D ) were determined at 20°C Example 1 Ethoxy carbony I -3 -cyclobuty I -D -a I any I -L-prolyl -L-argi- nine aldehyde (Eoc-D-Cba-Pro-Arg-H) hemisulfate Step 1 Ethoxy carbonyl-3-cy clobutyl-D-alanyl-L-p ro lyl- N G -benzyloxy-carbonyl-L-argιnιne-lactam 328 g (84 mmol) of t-butoxycarbonyl-N G -benzyloxy- carbonyl-L-argmine-lactame [S Bajusz and co-workers: J Med Chem 33, 1729 (1990)] is suspended in 8 ml of chloroform, then 10 ml of ethyl acetate, saturated with HCI gas (0 11-0 15 g/ml) is added with constant stirring and ice cooling The reaction is followed by thin layer chro- matography [R f (9)= 091 (Boc-compound), 007 (free com¬ pound)] At the end the reaction mixture is diluted with 18 of ml diethyl ether, the crystalline mass formed is filtered, washed with 5 ml of acetone and 5 ml of diethyl ether, then dried in a vacuum desiccator over potassium hydr- oxide pellets The N G -benzyloxycarbonyl-L-argιnιne lac¬ tam hydrochloride obtained is dissolved in 8 ml of di¬ methylformamide, cooled to -20 C° and added to the mixed anhydride prepared below 2 5 g (8 mmol) of ethoxycarbonyl-3-cyclobutyl-D-ala- nyl-L-prolme (Example 1, Step E) is dissolved in 8 ml of dimethylformamide cooled to -20 C° With constant stirring 09 ml (8 mmol) of N-methyl-morpholine and 1.05 ml (8 mmol) of isobutyl chloroformate are introduced, then, after 10 mm stirring, the above-mentioned N G -benzyloxy- carbonyl-L-arginine lactam hydrochloride solution and 235 ml (168 mmol) of tπethyl amine The reaction mixture is stirred for 30 minutes at -10 C°, then for an hour at 0 C° The salts are filtered and discarded, the filtrate is diluted with 40 ml of benzene The solution is washed with 3x10 ml of water, with 10 ml of 1M KHS0 4 -solutιon and again with 3x10 ml of water, dried over anhydrous so¬ dium sulphate and the solvent evaporated at a pressure of 20-2 5 kPa The resulting product is applied onto a column made of 70 g Kieselgel 60 and eluted with ethyl acetate The fractions containing pure material [R f (1) = 0 50] are pooled and the solvent evaporated at 20- 25 kPa The oily residue is rubbed with petroleum ether, filtered and dried Yield 3 0 g (64%), R f (1) = 0 50 The FAB mass spectra data confirm the expected structure (585 [M + H] + ) Step 2 Ethoxycarbonyl-3-cyclobutyl-D-alanyl-L-prolyl- N G -beπzyloxy-carbonyl-L-argιnιne aldehyde 2 27 g (46 mmol) of ethoxycarbonyl-3-cyclobutyl-D- alanyl-L-prolyl-N G -benzyloxycarbonyl-L-argιnιne lactam (Example 1, Step 1) is dissolved in 15 ml of tetrahydro- furan and 36 mmol of lithium aluminium hydride, dis¬ solved in tetrahydrofuran, is added at a temperature not higher than -50 C° with constant stirring The progress of the reaction is monitored by thin-layer chromatography in solvent system (6) and more lithium aluminium hydride is added when it is needed. Pre-cooled 0.5M sulphuric acid solution is added to the reaction mixture with constant stirring and cooling until the solution reaches pH3. The resulting solution is extracted with 2x15 ml of n-hexane, then with 3x20 ml of methylene chloride. The methylene chloride extracts are pooled, washed with 3x15 ml of water, 15 ml of cold 5% NaHCO 3 -solutιon, then again with 15 ml of water, dried over anhydrous sodium sulphate, and the solvent is evaporated at a pressure of 20-2 5 kPa The residue is dissolved in 10 ml of benzene and precipi¬ tated with cyclohexane After filtering and drying the product weighs 1.8 g (65%) R,(6) = 030, [α] D = -308° (c=1, in tetrahydrofuran) The FAB mass spectrum confirms the assumed structure (587 [M + H] + ) Step 3 Ethoxycarbonyl-3-cyclobutyl-D-alanyl-L-prolyl- -L-argmine aldehyde hemisulfate 1 58 g (2,7 mmol) of ethoxycarbonyl-3-cyclobutyl-D- alanyl-L-prolyl-N G -benzyloxycarbonyl-L-arg mine aldehyde (Example 1, Step 2) is dissolved in 14 ml of ethanol, 2,7 ml of 05M sulphuric acid, 32 ml of water and then 0 17 g of Pd/C catalyst, suspended in 6 ml of ethanol, are added and the system is hydrogenated at 10 C° The reaction, whose progress is monitored by thin-layer chromatography, is complete in 15 minutes The catalyst is filtered off and the solution is concentrated to a volume of 7-9 ml at a pres-sure of 2.0-2.5 kPa. The residue is diluted with 20 ml of water, extracted with 6 ml of methylene chloride, and the aqueous solution is allowed to stand at room temperature for 24 hours. The pH is then adjusted to 3.5 with Dowex AG 1-X8 resin in OH-cycle and the solution freeze-dried. Yield 1 0 g (78%), [α] D =-755° (c=1, in water). HPLC(I). k' = 553, 620 and 7 17 The FAB mass spectrum confirms the assumed structure (453 [M + H] + ) The starting material can be prepared as follows Ethoxycarbonyl-3-cyclobutyl-D-alanyl-L-proline (Eoc-D-Cba-Pro) Step A. Ethoxy carbonyl-3-cyclobutyl-DL-alanιne 10 g (70 mmol) of 3-cyclobutyl-DL-alanιne [A Burger et al , J Med Chem 6, 221 (1963)] is dissolved in 70 ml of 2M NaOH solution, cooled to +5 °C and 11 1 ml (1162 mmol) of ethyl chloroformate is added in drops with con¬ stant stirring Stirring is continued for 2 hours at this temperature, and for further 2 hours at room temperature The reaction mixture is then washed with 20 ml of diethyl ether and after acidifying the solution to pH1 extracted with 3x20 ml of ethyl acetate The pooled extracts are washed with brine, dried over anhydrous sodium sulphate and the solvent is evaporated at a pressure of 20-25 kPa The resulted oil is considered to be the pure product [Yield 131 g (87%), R f (7) = 08] and is used without further treatment in the next step Step B Methyl ethoxycarbonyl-3-cyclobutyl-DL-alanιnate 11 g (51 mmol) of ethoxycarbonyl-3-cyclobutyl-DL- alanine (Example 1, Step A) is dissolved in 100 ml of methanol, cooled to -15 C° and 10 ml (137 mmol) of thio- nyl chloride is added at constant stirring Stirring is con¬ tinued without further cooling When the reaction mixture reaches room temperature, stirring is continued for further 2 hours The solution is then evaporated at a pressure of 20-2 5 kPa The residual oil is dissolved in 40 ml of ethyl acetate washed with 10 ml of 1N HCI, 2x10 ml of 5% NaHC0 3 and 2x10 ml of water, dried over anhydrous sodium sulphate and evaporated to dryness at a pressure of 20-2 5 kPa The residue is considered to be pure [yield 108 g (92%), R,(1)=085, R,(6) = 065] and is used without further treatment in the next step Step C Methyl ethoxycarbonyl-3-cyclobutyl-D-alanιnate The enzymatic hydrolysis of acyl ammo acid methyl esters can be performed at pH = 7 5 in an automatic titrator which has two reaction vessels (one with a volume of 100 ml and another with 250 ml) The reagent is 1M NaOH solution. 108 g (47 mmol) of methyl ethoxycarbonyl-3-cyclo- butyl-DL-alaninate (synthesised in Step B) is dissolved in 20 ml of benzene in the 250 ml vessel of the titrator. 100 ml of water is added and the pH of the solution is adjusted to 7 5 with 1M NaOH under stirring 40 mg of enzyme [Subtilisin Carlsberg, Protease, Type VIII (Sigma)] is added, the pH readjusted to 7 5 and kept at this value during tit rat i on The enzymatic hydrolysis is complete in 3 hours The phases are separated From the aqueous phase pure ethoxy-carbonyl-3-cyclobutyl-L-alanine can be isolated The benzene phase is washed with 2x10 ml of 5% NaHC0 3 and 2x10 ml of water, dried over anhydrous so¬ dium sulphate and evaporated at a pressure of 2 0-2 5 kPa The resulting yellowish oil is considered to be pure and used without further treatment in the next step Step D Ethoxycarbonyl-3-cyclobutyl-D-alanιne The oily product of Step C is dissolved in 20 ml of ethanol, and 10 ml of 2 5M NaOH solution is added The mixture is stirred for 2 hours at room temperature and evaporated at a pressure of 2 0-2 5 kPa The residue is dissolved in 30 ml of water, washed with 10 ml of diethyl ether, acidified to pH = 1 with 3M hydrochloric acid and extracted with 3x10 ml of ethyl acetate The pooled or¬ ganic extracts are washed with brine, dried over anhyd- rous sodium sulphate and evaporated at a pressure of 20- 25 kPa Yield 43 g (90%) of an oily product [R,(2) = 0 8], of which the greater part is used in the next step, the remainder is converted to crystalline salt as follows 043 g (2 mmol) of oily ethoxycarbonyl-3-cyclobutyl- D-alanme (Example 1, Step D ) is dissolved in 10 ml of di¬ ethyl ether and 023 ml (2 1 mmol) of cyclohexyl amine is added The separated crystals are filtered, washed with diethyl ether and dried in a vacuum desiccator Yield 057 g (90%) M p 129 - 131 °C, [α]o=393° (c=1, in methanol) Analysis for C 16 H 30 N 2 O4 (314.42). Calculated: C%=61.12; H% = 9.62, N% = 8.91 Found: C% = 61.30; H%=980, N% = 8.60 Step E Ethoxycarbonyl-3-cyclobutyl-D-alanyl-L-prolιne 3 7 g (172 mmole) of ethoxycarbonyl-3-cyclobutyl- D-alanme (Example 1, Step D) is dissolved in 60 ml of tetrahydrofuran, cooled to 0 °C, then 485 g (24 5 mmol) of 2,4,5-tπchlorophenol and 506 g (24 5 mmol) of dicyclo- hexyl-carbodnmide are added The reaction mixture is stirred at room temperature for 2 hours, filtered from the separated dicyclohexylurea and washed with tetrahydro¬ furan The filtrate and the washings are pooled and evap¬ orated at a pressure of 2 0-2 5 kPa The residue is dis¬ solved in 25 ml of diethyl ether - petroleum ether mixture (1 1), the insoluble dicyclohexylurea is filtered off and the filtrate is evaporated again [the filtered dicyclohexylurea amounts to 4.9 g (89%) and 0.6 g (11%), respectively]. The oily 2,4,5-trichlorophenyl ethoxycarbonyl-3-cyclo- butyl-D-alaninate is dissolved in 40 ml of pyridine and 2.12 g (18.4 mmol) of finely pulverised L-proline is added together with 3.43 ml (24.6 mmol) of triethyl amine. The reaction mixture is stirred at room temperature for 3 hours, then evaporated at a pressure of 2.0-2.5 kPa. The residue is distributed between 50 ml of ethyl acetate and 50 ml of 1M HCI. The organic phase is washed first with 10 ml of 1M HCI then with 2x10 ml of water and is ex¬ tracted with 3x100 ml of 5% NaHC0 3 . The pooled hydro- carbonate extracts are acidified to pH3 with 6M HCI and extracted with 3x20 ml of diethyl ether. The ethereal extracts are pooled, washed acid-free with water, dried over anhydrous sodium sulphate and evaporated to dry¬ ness. Yield: 3.2 g (60%) oil. R,(6) = 0.49. The FAB mass spectrum (313 [M + H] + ) confirms the assumed structure. Example 2 Methoxy carbonyl-3-cy clobutyl-D-ala nyl-L-prolyl-N G - benzyloxycarbonyl-L-arginine aldehyde (MOC -D-Cba -Pro -Arg-H) hemi sulfate Step 1 : M ethoxy car bony I -3-cy do butyl -D -a I any I -L-prolyl - N G -benz loxy carbonyl-L-arginine lactam Starting with 1.64 g (4.2 mmol) of t-butoxycarbonyl- N G -benzyloxycarbonyl-L-arginine lactam [S Bajusz et al., J. Med. Chem. 33, 1729 (1990)] and 1.25 g (4.0 mmol) of methoxycarbonyl-3-cyclobutyl-D-alanyl-L-proline (Example 2, Step C), the coupling of these components and the chromatographic purification of the end-product is performed according to Example 1, Step 1 using pro¬ portional quantities of reagents and solvents. The frac- tions containing pure end-product [Rf(1) = 0] are pooled and evaporated at a pressure of 2.0-2.5 kPa The residue is rubbed with petroleum ether, filtered and dried in a desic¬ cator over paraffin turnings and phosphorus pentoxide Yield- 1 15 g (50%). R,(2) = 045-047. [α] D =-435° (c=1, in tetrahydrofuran) The FAB mass spectrum (571 [M + H] + , 724 [M + H + NBA] * ) confirms the assumed structure Step 2 Methoxycarbonyl-3-cyclobutyl-D-alanyl-L-prolyl- N G -benzyloxycarbonyl-L-arg mine aldehyde 1.06 g (1 8 mmol) of methoxycarbonyl-3-cyclobutyl-D- alanyl-L-prolyl-L-arginine lactam (Example 2, Step 1) is reduced according to the method described in Example 1, Step 2, using proportional quantities of reagents and sol¬ vents. Yield- 076 g (73%). R f (9) = 0.47 [α] D = -37.5 ° (c=1 in tetrahydrofuran) The FAB mass spectrum (573 [M + H] + , 726 [M + H + NBA] * ) confirms the assumed structure Step 3: Methoxycarbonyl-3-cyclobutyl-D-alanyl-L-prolyl- N G -benzyloxycarbonyl-L-argιnine aldehyde hemi- sulfate 0.69 g (1.2 mmol) of methoxycarbonyl-3-cyclobutyl-D- alanyl-L-prolyl-N G -benzyloxycarbonyl-L-argιπine aldehyde (Example 2, Step 2) is subjected to hydrogenolysis ac¬ cording to the method described in Example 1, Step 3, using proportional quantities of reagents and solvents Yield- 0.53 g (91%) HPLC(II) k' = 474, 547 and 582 [α] D = -609° (c=1 , in water) The FAB mass spectrum (439 [M + H]\ 592 [M + H + NBAJ + confirms the assumed structure The starting material can be prepared as follows M ethoxy carbonyl-3-cyclobutyl-D-alanyl-L-pro line (MOC- D-Cba-Pro) Step A: Methoxy carbonyl-3-cyclobutyl-DL-alanιne 43 g (30 mmol) of 3-cyclobutyl-DL-alanιne [A Burger et al., J Med. Chem. 6, 221 (1963)] is dissolved in 15 ml of 2M NaOH solution, cooled to 0 °C and simultaneously 165 ml of 2M NaOH solution and 2 55 ml (33 mmol) of methyl chloroformate are added with vigorous stirring. Stirring is continued at this temperature for 30 minutes and at room temperature for 2 hours. The reaction mixture is diluted with 40 ml of water, extracted with 10 ml of diethyl ether, then acidified to pH3 with 3M HCI. The product is extracted with ethyl acetate (4x20 ml), the extracts are pooled, washed with 20 ml of water, dried over anhydrous sodium sulphate and evaporated at a pressure of 2.0-2.5 kPa. The oily residue [5.3 g (88%), R f (7) = 0.61] is used without further purification in the next step. Step B: Methoxycarbonyl-3-cyclobutyl-D-alanine 5.03 g (25 mmol) of methoxycarbonyl-3-cyclobutyl- DL-alanine (Example 2, Step A) is treated according to the method described in Example 1, Steps B-D, using propor¬ tional quantities of reagents and solvents. Yield: 2.22 g (11 mmol) oily product. Step C: Methoxy carbonyl-3-cyclobutyl-D-alanyl-L-pro line 1.21 g (6 mmol) of methoxycarbonyl-3-cyclobutyl-D- alanine (Example 2, Step B) is treated according to the method described in Example 1, Step E, using proportional quantities of reagents and solvents. Yield: 1.6 g (5.4 mmol, 90%) oily product [R f (9) = 0.48], the larger part of which is used directly in Step 1, while the remainder is converted to a crystalline salt as follows 030 g (1 mmol) of oily methoxycarbonyl-3-cyclobutyl- D-alanyl-L-prohne is dissolved in 5 ml of diethyl ether and 021 ml (1 05 mmol) of dicyclohexyl amine is added The separated crystals are filtered off, washed with diethyl ether and dried in a vacuum desiccator Yield 043 g (90%) M p 1495-164°C Analysis for C 2 H45N 3 θ5 (47964) Calculated C% = 65 10, H% = 946, N% = 876, Found C% = 604, H% = 898, N% = 1047 Example 3 lsopropoxycarbonyl-3-cyclobutyI-D-alanyl-L-prolyl-L- arginine aldehyde (iPoc-D-Cba-Pro-Arg-H) hemisulfate Step 1 lsopropoxycarbonyl-3-cyclobutyl-D-alanyl-L-prolyl- N G -benzyloxycarbonyl-L-argιnιne lactam Starting with 043 g (1 1 mmol) of t-butoxycarbonyl- N G -benzyloxycarbonyl-L-argιnιne lactam [S Bajusz et al , J Med Chem 33, 1729 (1990)] and 033 g (1 mmol) of ιsopropoxycarbonyl-3-cyclobutyl-D-alanyl-L-prolιne (Ex¬ ample 3, Step C) the components are coupled and the product chromatographically purified according to the method described in Example 1, Step 1, using proportional quantities of reagents and solvents The fractions con¬ taining pure end-product [R f (1) = 055] are pooled, evap¬ orated at a pressure of 20-2 5 kPa, the residue is rubbed with petroleum ether, filtered and dried in a desiccator Yield 03 g (50%) R f (1) = 055 The FAB mass spectrum (599 [M + H]\ 752 [M + H + NBA] * ) confirms the assumed structure Step 2 lsopropoxycarbonyl-3-cyclobutyl-D-alanyl-L-prolyl- N G -benzyloxycarbonyl-L-argιnιne aldehyde 026 g (043 mmol) of ιsopropoxycarbonyl-3-cyclo- butyl-D-alanyl-L-prolyl-N G -benzyloxycarbonyl-L-argιnιne lactam (Example 2, Step 1) is hydrogenated according to the method described in Example 1, Step 2 using propor¬ tional quantities of reagents and solvents Yield 0 15 g R,(6) = 030 The FAB mass spectrum (601 [M + H] + , 754 [M + H + NBA] * ) confirms the assumed structure Step 3 lsopropoxycarbonyl-3-cyclobutyl-D-alanyl-L-prolyl- -L-arginme aldehyde hemisulfate 013 g (02 mmol) of ιsopropoxycarbonyl-3-cyclobutyl-D- alanyl-L-prolyl-N G -benzyloxycarbonyl-L-argιnιne aldehyde (Example 2, Step 2) is treated according to the method described in Example 1, Step 3, using proportional quantities of reagents and solvents Yield: 0.07 g (75%). HPLC(I): k' = 3.69; 4.15 and 5.04. The FAB mass spectrum (467 [M + H] + , 620 [M + H + NBA] * ) confirms the assumed structure. The starting material can be prepared as follows. lsopropoxycarbonyl-3-cyclobutyl-D-alanyl-L-proline (IPoc-D-Cba-Pro) Step A. 3-Cyclobutyl-D-alanine To 1.0 g (5 mmol) of methoxycarbonyl-3-cyclobutyl-D- alanine (Example 2, Step 2) 10 ml of 6M HCI is added and heated to reflux for 3 hours The solution is evaporated at a pressure of 2 0-2 5 kPa, the residue is dissolved in 5 ml of water and evaporated to dryness and this process is repeated The traces of water can be removed by azeo¬ tropic distillation with ethanol-benzene mixture The res¬ idual oil is dissolved in 10 ml of ethanol and 5 mmol of 1 ,2-epoxy-propane is added After cooling the precipitate is filtered off, the solid is washed with diethyl ether and dried. Yield: 0.65 g (90%) of 3-cyclobutyl-D-alanιne. R,(13) = 0.65 [α] D = -34.7° (c=1, in 1M HCI). Analysis for C 7 H 13 N0 2 . Calculated C% = 58 71, H = 9 15, N% = 978, Found C% = 58.70, H% = 9.30; N% = 950 Step B lsopropoxycarbonyl-3-cyclobutyl-D-alanιne 057 g (4 mmol) of 3-cyclobutyl-D-alanιne is dis¬ solved in 8 ml 1 1 mixture of 1M NaOH solution and di¬ oxane The mixture is cooled to 0 °C and simultaneously 4 ml of 1M NaOH solution and 4 ml of isopropyl chloro¬ formate (cone 1M in toluene) solution are added with vigorous stirring The reaction mixture is stirred for 1 hour at this temperature and for 5 hours at room temperature Dioxane and toluene are distilled off at a pressure of 2 0- 25 kPa The remaining aqueous solution is washed with 5 ml of diethyl ether, then acidified to ρH3 with 1M KHSO, solution The emulsion is extracted with 3x5 ml of ethyl acetate, the pooled extracts are washed with water and dried over anhydrous sodium sulphate After evaporating at a pressure of 20-2 5 kPa the yield is 083 g (90%) R f (6) = 060, [α] D = +95° (c = 05, in methanol) Step C lsopropoxycarbonyl-3-cyclobutyl-D-alanyl-L- -proline 046 g (2 mmol) of ιsopropoxycarbonyl-3-cyclobutyl- D-alanme (Example 3, Step B) is treated according to the method described in Example 1, Step E, using propor¬ tional quantities of reagents and solvents Yield 1 3 g (435 mmol, 87%) oil R,(2) = 040 The FAB mass spectrum (327 [M + H] * ) confirms the assumed structure Example 4 Ethoxy carbony I -3 -cyclopent l -D-al any I -L-prolyl -L- arginine aldehyde (Eoc-D-Cpa-Pro-Arg-H) hemisulfate Step 1 Ethoxycarbonyl-3-cyclopentyl-D-alanyl-L-prolyl- -N G -benzyl-oxycarbonyl-L-argιnιne lactam 293 g (7 5 mmol) of t-butoxycarbonyl-N G -benzyloxy- carbonyl-L-arginine lactam [S Bajusz et al , J Med Chem 33, 1729 (1990)] and 2 3 g (7 1 mmol) of ethoxy- carbonyl-3-cyclopentyl-D-alanyl-L-prolιne (Example 4, Step C) are treated according to the method described in Example 1, Step 1, using proportional quantities of re¬ agents and solvents The fractions containing pure end- product [R f (1) = 055] are pooled, evaporated at a pressure of 20-2 5 kPa, the remaining oil is rubbed with n-hexane, filtered off, washed with n-hexane and dried in a vacuum desiccator Yield 2 5 g (59%) Rι(1) = 0 55, [α] D = -486° (c=1, in tetrahydrofuran) The FAB mass spectrum (599 [M + H] + , 752 [M + H + NBA] * ) confirms the assumed structure Step 2 E thoxycarb on y I- 3-cy elope nty I -D-al any I -L-prolyl ■ ■ N G -benzyloxycarbonyl-L-arg mine aldehyde 2 34 g (39 mmol) of ethoxycarbonyl-3-cyclopentyl-D- alanyl-L-prolyl-N G -benzyloxycarbonyl-L-argιnιne lactam (Example 4, Step 1) is reduced according to the method descπbed in Example 1, Step 2, using proportional quanti¬ ties of reagents and solvents. Yield: 1.75 g (74.7%). R,(6) = 0.42, [α] D = -344° (c=1, in tetrahydrofuran). The FAB mass spectrum (601 [M + H] * , 754 [M + H + NBA] * ) confirms the assumed structure Step 3 Ethoxycarbonyl-3-cyclopentyl-D-alanyl-L-prolyl-L- -arginine aldehyde hemisulfate 1 59 g (265 mmol) of ethoxycarbonyl-3-cyclopentyl- D-alanyl-L-prolyl-N G -benzyloxycarbonyl-L-argιnιne alde¬ hyde (Example 4, Step 2) is hydrogenated according to the method described in Example 1, Step 3, using proporti- onal quantities of reagents and solvents Yield 1 13 g (83%) R f (3)= 0 37 [α] 0 = -344° (c=1, in water). HPLC(I) k' = 4 76, 540 and 7 32 The FAB mass spectrum (467 [M + H]\ 620 [M + H + NBA] * ) confirms the assumed structure The starting material can be prepared as follows Ethoxycarbony I -3-cyclopenty I -D-al any I -L-proline (Eoc-D-Cpa-Pro) Step A Ethoxycarbony l-3-cyclopentyl-DL-alanιne 787 g (50 mmol) of 3-cyclopentyl-DL-alanιne [P R Pal et al , J Am Chem Soc , 78, 5116 (1956)] is treated according to the method described in Example 1, Step A, using proportional quantities of reagents and solvents, with the exception that the product from the reaction mix- ture is extracted with 2x50 ml diethyl ether dried over an¬ hydrous sodium sulphate and evaporated at a pressure of 20-2 5 kPa Yield 10 55 g (98%) of white, amorphous powder [R,(2) = 084] which is used without further puri¬ fication in the next step Step B Ethoxycarbonyl-3-cyclopentyl-D-alanιne 7 8 g (34 mmol) of ethoxycarbonyl-3-cyclopentyl-DL- alanine (Example 4, Step A) is treated according to the method described in Example 1 Steps B,C D using propor¬ tional quantities of reagents and solvents Yield 345 g (886%) of an oil [R f (6)= 0062], the larger part of which is used directly in Step C The remainder is converted to a crystalline salt as follows 046 g (2 mmol) of oily ethoxycarbonyl-3-cyclopentyl- D-alanine is dissolved in 10 ml of diethyl ether and 042 ml (2 1 mmol) of dicyclohexyl amine is added The preci¬ pitate is filtered off, washed with diethyl ether and dried in a vacuum desiccator Yield 074 g (90%) crystalline salt M p 138-140 °C, [α] D = -1 5° (c=1, methanol) Analysis for C 23 H42N 2 θ (41058) Calculated C%=6728, H % = 1031, N% = 681, Found C% = 6740, H% = 1040, N% = 680 Step C Ethoxycarbonyl-3-cyclopentyl-D-alanyl-L-prolιne 2 43 g (105 mmol) of ethoxycarbonyl-3-cyclopentyl- D-alanme (Example 4, Step B) is treated according to the method described in Example 1, Step E, using proportional quantities of reagents and solvents The resulting 2,4,5- trichlorophenylester is coupled with 1 15 g (10 mmol) of L- pro ne which yields 23 g (71%) of an oily product R f (6)= 0 53 The FAB mass spectrum (327 [M + H] * ) confirms the assumed structure Synthesis of control compounds Synthesis 1 Ethoxycarbony I -3 -phenyl -D-al any I -L-prolyl -L -arginine aldehyde (Eoc-D-Phe-Pro-Arg-H) hemisulfate Step 1 : Ethoxycarbonyl-3-ρhenyl-D-alan l-L-ρrolyl-N G - -benzyloxycarbonyl-L-arginine lactam Starting with 2.3 g (5.8 mmol) of t-butoxycarbonyl-N G - benzyloxycarbonyl-L-arginine lactam [S. Bajusz et al., J. Med. Chem. 33, 1729 (1990)] and 1.67 g (5 mmol) of ethoxycarbonyl-3-phenyl-D-alanyl-L-proline (Synthesis 1, Step C), the coupling of the components and the purifica- tion of the product is performed according to the method described in Example 1, Step 1, using proportional quan¬ tities of reagents and solvents. The fractions containing pure product [R f (1)= 0.37] are pooled and evaporated at a pressure of 2.0-2.5 kPa. The residue is dried in a vacuum desiccator. Yield: 1.18 g (60%) of an oil. The FAB mass spectrum (607 [M + H] * ) confirms the assumed structure. Step 2. Ethoxycarbonyl-3-pheπyl-D-alanyl-L-prolyl-N G - -benzyloxy carbonyl-L-arginine aldehyde 0.9 g (1.5 mmol) of ethoxycarbonyl-3-phenyl-D- a I anyl-L-prolyl-N G -benzy I oxy carbonyl-L-arginine lactam (Synthesis 1, Step 1) is reduced according to the method described in Example 1, Step 2, using proportional quan¬ tities of reagents and solvents. Yield: 0.33 g (36%). R,(1)= 0.16 Step 3 Ethoxy carbonyl-3-phenyl-D-alanyl-L-prolyl-L- -arginine aldehyde hemisulfate 0.33 g (054 mmol) of ethoxycarbonyl-3-phenyl-D- alanyl-L-prolyl-N G -benzyloxycarbonyl-L-argιniπe aldehyde (Synthesis 1, Step 2) is treated according to the method described in Example 1, Step 3, using proportional quanti¬ ties of reagents and solvents Yield- 026 g (92%). HPLC(I) k' = 4.00; 445 and 545 The FAB mass spectrum (475 [M + H] * , 628 [M + H + NBA] * ) confirms the assumed structure The starting material can be prepared as follows Ethoxycarbonyl-3-phenyl-D-alanyl-L-proline (Eoc-D-Phe-Pro) Step A Ethoxycarbonyl-3-phenyl-D-alanιne 165 g (0 1 mole) of 3-phenyl-D-alanιne is treated ac¬ cording to the method described in Example 1, Step A, using proportional quantities of reagents and solvents with the exception that after evaporating the solvent from the ethyl acetate solution of the end product, the resulting oil is dried in a vacuum desiccator Yield 146 g (55%) R,(9)= 070 Step B Ethoxycarbonyl-3-phenyl-D-alanιne N-hydroxy- -succinimidate 14 5 g (554 mmol) of ethoxycarbonyl-3-phenyl-D- alanine (Synthesis 1, Step A) and 64 g (56 mmol) of N- hydroxy-succinimide are dissolved in 60 ml of tetrahydro¬ furan The solution is cooled to 0 °C and 11 5 g (56 mmol) of dicyclohexyl-carbodiimide is added while stirring Stirring is continued at this temperature for 10 hours, then the mixture is filtered and the filtrate evaporated at a pressure of 2 0-25 kPa The residue is crystallised from benzene The crystals are filtered washed with benzene and diethyl ether and dried in a vacuum desiccator Yield 11 3 g (60%) R r (10)= 053, [α] D = +58 1° (c=1, dimethylformamide) The FAB mass spectrum (335 [M + H] * ) confirms the as¬ sumed structure Analysis for Cι 6 Hι 8 N 2 0 6 (334 33) Calculated C% = 5748, H% = 542 N% = 8 30, Found C% = 5740, H% = 540 N% = 8 30 Step C Ethoxycarbony l-3-phenyl-D-alany I- L -pro line 3 34 g (10 mmol) of ethoxycarbonyl-3-phenyl-D- alanine hydroxysuccinimidate (Synthesis 1, Step B) is dissolved in 15 ml of pyridine and 1 15 g (10 mmol) of L- proline and 1 4 ml (10 mmol) of triethylamine are added The reaction mixture is stirred at room temperature for 10 hours, then evaporated at a pressure of 2 0-2 5 kPa The residue is distributed between 30 ml 5% NaHC0 3 solution and 10 ml of diethyl ether The aqueous phase is washed with 3x5 ml of diethyl ether, the pooled organic washings are extracted with 5 ml 5% NaHC0 3 -solutιon The bicarbo¬ nate phases are pooled, acidified with 1 KHS0 4 solution to pH3 and extracted with 3x10 ml of ethyl acetate The pooled organic extracts are dried over anhydrous sodium sulphate and evaporated at a pressure of 2 0-2 5 kPa The oily residue is crystallised with diethyl ether, the crystals are filtered, washed with diethyl ether and dried in a vacuum desiccator Yield 2 6 g (77%) M p 141-143 °C, R,(6)= 040 The FAB mass spectrum (335 [M + H] * ) confirms the assumed structure Analysis for C17H22 2O5 (33433) Calculated C% = 61 06, H% = 663, N% = 8 38, Found C% = 61 10, H% = 670, N% = 8 1 Synthesis 2 Methoxycarbonyl-3-phenyl-D-alanyl-L-prolyl-L-arginine aldehyde (Moc-D-Phe-Pro-Arg-H) hemisulfate Step 1 Methoxy carbonyl -3 -phenyl-D-alanyl-L-p ro lyl-N G - -benzyloxycarbonyl-L-argmine lactam Starting with 4 1 g (105 mmol) of t-butoxycarbonyl- N G -benzyloxycarbonyl-L-argιnιne lactam [S Bajusz et al , J Med Chem 33, 1729 (1990)] and 2 88 g (9 mmol) of methoxycarbonyl-3-phenyl-D-alanyl-L-proline (Synthesis 1, Step C) the coupling is performed according to the method described in Example 1, Step 1 using proportional quantities of reagents and solvents. The crude product is purified by crystallising from cyclohexane. Yield: 4.65 g (86%). M.p.: 72-82.7 °C. R ( (2)= 0.56. [α] D = +72.9° (c=1, in tetrahydrofuran). The FAB mass spectrum (593 [M + H] * , 46 [M + H + NBA] * ) confirms the assumed structure. Step 2: Methoxycarbonyl-3-phenyl-D-alanyl-L-prolyl-N - -benzyloxycarbonyl-L-arginine aldehyde 4.13 g (7 mmol) of methoxycarbonyl-3-phenyl-D- -alanyl-L-prolyl-N G -benzyloxycarbonyl-L-arginine lactam (Synthesis 2, Step 1) is reduced according to the method described in Example 1, Step 2, using proportional quan¬ tities of reagents and solvents with the exception that after evaporating the methylene chloride solvent the oily end product is crystallised with diethyl ether. The crystals are filtered, washed with diethyl ether and dried in a vacuum desiccator. Yield: 3.06 g (74%). M.p.: 103-107 °C. R f (6) = 0.44. [α] D = -69° (c=1, in tetrahydrofuran). The FAB mass spectrum (595 [M + H] * , 748 [M + H + NBA] * ) confirms the assumed structure Step 3 Methoxycarbonyl-3-phenyl-D-alanyl-L-prolyl-L- -arginine aldehyde hemisulfate 2.68 g (4.5 mmol) of methoxycarbonyl-3-phenyl-D- aianyl-L-prolyl-N G -benzyloxycarbonyl-L-arginine aldehyde (Synthesis 2, Step 2) is treated according to the method described in Example 1, Step 2, using proportional quanti¬ ties of reagents and solvents. Yield. 2.15 g (94%) [α] D = -876° (c=1, in water) HPLC(I) k' = 33, 3.57 and 409 The FAB mass spectrum (461 [M + H] * , 614 [M + H + NBA] * ) confirms the assumed structure. The starting material can be prepared as follows Methoxycarbonyl-3-phenyl-D-alanyl-L-proIine (Moc-D-Phe-Pro) Step A Methoxycarbonyl-3-phenyl-D-alanιne dicyclohexyl- -amine salt 5 g (30 mmol) of D-phenylalanme is dissolved in 15 ml of 2M NaOH solution, cooled to 0 °C and, simultane¬ ously, 165 ml of 2M NaOH solution and 2 55 ml (33 mmol) of methyl chloroformate are added The mixture is stirred at this temperature for 30 mm, then at room temperature for 2 hours. Diluted with 40 ml of water, the mixture is washed with 10 ml of diethyl ether, acidified to pH3 with 3M HCI and extracted with 4x20 ml of ethyl acetate. The pooled organic extracts are washed with water (20 ml), dried over anhydrous sodium sulphate and evaporated at a pressure of 2.0-2.5 kPa. The residue is dissolved in 60 ml of diisopropyl ether and 6 ml (30 mmol) of dicyclohexyl- amine is added. The separated crystals are filtered off, washed with diisopropyl ether and dried in air. Yield: 11.5 g (28.5%). M.p.: 167-170 °C. [α] D = -37.9° (c=0.5, in ethanol). Analysis for C 23 H 36 N 2 θ4 (404.53): Calculated: C% = 68.28; H% = 8.97; N% = 6.92; Found: C% = 68.30; H% = 9.15; N% = 6.75. Step B: Methoxycarbonyl-3-phenyl-D-alanιne 2,4,5- -trichlorophenyl ester 11.3 g (28 mmol) of methoxycarbonyl-3-phenyl-D- alanine dicyclohexylammonium salt (Synthesis 2, Step A) is distributed between 75 ml of ethyl acetate and 30.5 ml of 1M KHS0 4 . The phases are separated, the organic phase is washed neutral with water, dried over anhydrous sodium sulphate and concentrated at a pressure of 2.0-2.5 kPa to a volume of 15 ml. To the cooled (approx. 0 °C) residue 5.5 g (28 mmol) of 2,4,5-trichlorophenol and 5,75 g (28 mmol) of dicyclohexyl carbodiimide are added and the reaction mixture is allowed to stand overnight. The separated dicyclohexylurea is filtered off, and the filtrate evaporated. The oily residue is crystallised from ethanol. The crystals are filtered, washed with diethyl ether and dried in a vacuum desiccator. Yield: 6.86 g (61%). M.p.: 109-110 °C. R f (4)= 0.84. Analysis for Ci7H 14 N0 4 Cl3 (402.66): Calculated: C% = 50.70; H% = 3.50; N% = 3.48; Cl% = 26.42 Found: C% = 50.80; H% = 3.20; N% = 3.40; Cl% = 26.60. Step C: Methoxycarbonyl-3-phenyl-D-alanyl-L-proline 4.83 g (12 mmol) of methoxycarbonyl-3-phenyl-D- alanyl-2,4,5-trichlorophenyl ester (Synthesis 2, Step B) is dissolved in 12 ml of pyridine, then 1.38 g (12 mmol) of finely pulverised L-proline and 1.68 ml (12 mmol) of tri- ethyl amine are added with stirring. The reaction mixture is stirred for 16 hours, then evaporated at a pressure of 2.0-2.5 kPa. The residue is dissolved in 40 ml of 5% NaHC0 3 and the solution is extracted with 3x7 ml of di¬ ethyl ether. The pooled ethereal phases are washed with 7 ml of 5% NaHC0 3 . The bicarbonate washings are pooled, acidified to pH3 with 3M HCI and extracted with 3x10 ml of ethyl acetate. The extracts are dried over anhydrous so¬ dium sulphate and evaporated at a pressure of 2.0-2.5 kPa. The residue is crystallised with diethyl ether, the crystals are filtered, washed with diethyl ether and dried in a vacuum desiccator. Yield: 3.05 g (79%). M.p.: 154-157 °C. R,(2) = 0.47. The FAB mass spectrum (321 [M + H]*) confirms the assumed structure. Synthesis 3 Ethoxy car bony I -3 -cyclobuty I -DL-al any I -L-prolyl -L- arginine aldehyde (Eoc-DL-Cba-Pro-Arg-H) hemisulfate Step 1 : Ethoxycarbonyl-3-cyclobutyl-DL-alanyl-L-prolyl- -N G -benzyloxy carbonyl-L-arginine lactam Starting with 1.35 g (3.46 mmol) of t-butoxycarbonyl- N G -benzyloxycarbonyl-L-arginine lactam [S. Bajusz et al., J. Med. Chem. 33, 1729 (1990)] and 1.03 g (3.3 mmol) of ethoxycarbonyl-3-cyclobutyl-DL-alanyl-L-proline (Syn¬ thesis 3, Step A) the coupling of the components and the chromatographic purification of the end product are per¬ formed according to the method described in Example 1, Step 1, using proportional quantities of reagents and solvents. The fractions containing pure end-product [R f (1) = 0.50] are pooled, evaporated at a pressure of 2.0- 2.5 kPa, the residue is triturated with n-hexane, filtered, washed with n-hexane and dried in a vacuum desiccator. Yield: 1.0 g (51%). R f (1) = 0.50. ESI mass spectrum (585 [M + H]*) confirms the assumed structure. Step 2: Ethoxycarbony l-3-cyclobutyl-DL-alany I -L-proly I- -N G -benzyloxycarbonyl-L-arginine aldehyde 0.94 g (1.6 mmol) of ethoxycarbonyl-3-cyclobutyl-DL- alanyl-L-prolyl-N G -benzyloxycarbonyl-L-arginine lactam (Synthesis 3, Step 1) is reduced according to the method described in Example 1, Step 2 using proportional quanti¬ ties of reagents and solvents. Yield: 0.64 g (68%). R,(6) = 0.30. ESI mass spectrum (587 [M + H]*) confirms the assumed structure. Step 3: Ethoxycarbonyl-3-cyclobutyl-DL-alanyl-L-prolyl-L- -arginine aldehyde hemisulfate 0.59 g (1.0 mmol) of ethoxycarbonyl-3-cyclobutyl-DL- al any I -L-proly l-N G -benzyloxycarbony I -L-argi nine aldehyde (Synthesis 3, Step 2) is treated according to the method described in Example 1, Step 3 using proportional quanti- ties of reagents and solvents. Yield: 0.39 g (78%). HPLC(I): k' = 5.55; 6.27 and 7.09. The FAB mass spectrum (453 [M + H]*, 606 [M + H + NBA]*) confirms the assumed structure. The starting material can be prepared as follows: Ethoxycarbony I -3-cyclobuty I -DL-al any I -L-proline (Eoc-DL-Cba-Pro) Step A: Ethoxycarbonyl-3-cyclobutyl-DL-alany I -L-proline 1.13 g (5.25 mmol) of ethoxycarbonyl-3-cyclobutyl- DL-alanine (Example 1, Step A) is treated according to the method described in Example 1, Step E using proportional quantities of reagents and solvents to yield the oily 2,4,5- trichlorophenyl ester which is then coupled with 0.58 g (5.0 mmol) of finely pulverised L-proline Yield: 1.1 g (71%) of an oil. R,(6) = 0.53. ESI mass spectrum (313 [M + H] * ) confirms the assumed structure. Synthesis 4 Ethoxy carbony I -3 -cyclopentyl -DL-al any I -L-proly I -L- arginine aldehyde (Eoc-DL-Cpa-Pro-Arg-H) hemisulfate Step 1 : Ethoxycarbonyl-3-cyclopentyl-DL-alanyl-L-prolyl- -N G -benzyloxycarbonyl-L-arginιne lactam Starting with 3.7 g (9.5 mmol) of t-butoxycarbonyl-N G - benzyloxycarbonyl-L-arginine lactam [S. Bajusz et al. J. Med. Chem. 33, 1729 (1990)] and 2.94 g (9.0 mmol) of ethoxycarbonyl-3-cyclopentyl-DL-alanyl-L-proline (Syn- thesis 4, Step A), the compounds are treated according to the method described in Example 1, Step 1 using propor¬ tional quantities of reagents and solvents. The fractions containing pure end product are pooled, evaporated at a pressure of 2.0-2.5 kPa and the residue is triturated with n-hexane. The solid product is filtered, washed with n- hexane and dried in a vacuum desiccator. Yield: 2.87 g (54%). R,(1)=0.55. ESI mass spectrum (599 [M + H]*) confirms the assumed structure. Step 2: Ethoxycarbonyl-3-cyclopentyl-DL-alanyl-L-prolyl- -N G -benzyloxycarbonyl-L-arginine aldehyde 2.75 g (4.6 mmol) of ethoxycarbonyl-3-cyclopentyl- DL-a I any I -L-proly l-N G -benzyloxycarbonyl-L-argi nine lactam (Synthesis 4, Step 1) is reduced according to the method described in Example 1, Step 2 using proportional quanti¬ ties of reagents and solvents. Yield: 1.74 g (64%). R f (6)=0.42. ESI mass spectrum (601 [M + H]*) confirms the assumed structure. Step 3: Ethoxy carbon y I -3-cy elope nty I -DL-alanyl-L- prolyl-L-arginine aldehyde hemisulfate 1.2 g (2.0 mmol) of ethoxycarbonyl-3-cyclopentyl-DL- alanyl-L-prolyl-N G -benzyloxycarbonyl-L-arginine aldehyde (Synthesis 4, Step 2) is treated according to the method described in Example 1, Step 3, using proportional quanti¬ ties of reagents and solvents. Yield: 0.8 g (78%). HPLC(I): k' = 3.96; 4.4 and 4.92. The FAB mass spectrum (467 [M + H]*, 620 [M + H + NBA]*) confirms the assumed structure. The starting material can be prepared as follows: Ethoxycarbonyl-3-cyclopentyl-DL-alanyl-L-proline (Eoc-DL-Cpa-Pro) Step A: Ethoxycarbonyl-3-cyclopentyl-DL-alanyl-L-proline 3.1 g (13,5 mmol) of ethoxycarbonyl-3-cyclopentyl- -DL-alanine (Example 4, Step A) is treated according to the method described in Example 1, Step E using propor¬ tional quantities of reagents and solvents to yield the oily 2,4,5-trichlorophenyl ester which is then coupled with L- proline. Yield: 3.1 g (74%). R f (6) = 0.50. ESI mass spectrum (327 [M + H]*) confirms the assumed structure. Synthesis 5 Ethoxycarbony l-DL-cyclobutyl-glycy I -L-prolyl -L-argi- nine aldehyde (Eoc-DL-Cbg-Pro-Arg-H) hemisulfate Starting with 1.2 g (3.0 mmol) of t-butoxycarbonyl- N G -benzyloxycarbonyl-L-arginine lactam [S. Bajusz et al, J. Med. Chem. 33, 1729 (1990)] and 0.69 g (2.3 mmol) of ethoxycarbonyl-DL-cyclobutyl-glycyl-L-proline (Synthesis 5, Step A), the coupling to the respective blocked tripep¬ tide lactam [R f (1)=0.32], the reduction to the blocked tri¬ peptide aldehyde [R f (9)=0.53] and the deblocking are per¬ formed according to the method described in Example 1, Steps 1, 2 and 3, using proportional quantities of reagents and solvents. Yield: 0.22 g. HPLC(I): k' = 2.74; 2.96 and 3.41. The FAB mass spectrum(439 [M + H]*, 592 [M + H + NBA]*) confirms the assumed structure. The starting material can be prepared as follows: Ethoxy carbony I -DL-cyclobuty I -gly cy I -L-proline (Eoc-DL-Cbg-Pro) Step A: Ethoxy carbony l-DL-cyclobutyl-glycyl-L-proline 0.78 g (6.0 mmol) of DL-cyclobutyl-glycine [T. H. Porter et al., Arch. Biochem. Biophys, 179, 266 (1977)] is acylated [R f (7) = 0.60], made to react with 2,4,5-trichloro- phenol [R f (4)=0.84] then coupled with L-proline according to the method described in Example 1, Steps A and E, using proportional quantities of reagents and solvents. Yield. 03.68 g (50%) of an oil. R,(2)=0.17 and 0.22. The FAB mass spectrum (299 [M + H]*) confirms the assumed structure. METHODS Method M1 Preparation of clots from human plasma a) Platelet-rich plasma is prepared by centrifuging a 9:1 mixture of human blood and 3.8% sodium citrate solution for 5 min. at 240 x g. b) 200 μl platelet-rich plasma and 80 μl 40 mM CaCI 2 so- lution are allowed to stand at room temperature for 1 hour. The thus-formed clot is washed with 6x2 ml of 0.9% NaCl solution with gentle stirring to remove the residual en¬ zymes (thrombin and factor X a ). The washing medium is assayed for thrombin-like activity as follows: c) To 400 μl of washing medium 100 μl of 1 mM Tos-Gly- Pro-Arg-pNA substrate solution is added, the mixture is incubated for 30 min at 37 °C, then the reaction is stopped with 100 μl of 50% acetic acid. From this mixture 150 μl aliquots are applied onto a 96-well microtitre plate and the extinction coefficients are measured at 405 nm (ELISA READER SLT Laborinstrument GmbH, Austria). In case of efficient washing the extinction coefficient is smaller than 5% of that of the control. Method M2 Determination of the inhibition of clot-bound factor Xa a) 0.1 - 1.0 - 10 and 100 μg/ml solutions are prepared from the peptide inhibitor in 0.1M Tris-buffer containing 0.02% human albumin (pH=8.5). b) After draining off the washing medium (Method 1), 400 μl of peptide solution (3 parallel samples for every con¬ centration) is added to the clot and incubated together with 400 μl of buffer as a control for 5 min. at 37 °C. Then 100 μl of 2 mM Moc-D-Chg-Gly-Arg-pNA substrate solution is added to each vessel and incubated for another 30 min at 37 °C. The reaction is stopped with 100 μl of 50% AcOH. c) From each reaction vessel 150 μl is applied onto a 96- well microtitre plate and extinction coefficients are measured at 405 nm (ELISA READER SLT Laborinstrument GmbH, Austria). IC 5 o (peptide concentration needed for 50% inhibition) is determined graphically from the average extinctions compared to the control. Method M3 Determination of the inhibition of clot-bound thrombin a) Solutions are made from the peptide inhibitors accord- ing to Method M2/a. b) After draining off the washing medium the clots (Method M1) are mixed with 400 μl of peptide solution (3 parallel samples with each concentration), then the samples are incubated for 5 min. at 37 °C together with a separate 400 μl buffer serving as control. Then 100 μl of 1 mM Tos-Gly- Pro-Arg-pNA substrate solution is added and the incuba¬ tion continued for further 30 min. at 37 °C. The experiment is continued according to M2/c. Method M4 Preparation of fibrin clots a) To each reaction vessel 200 μl of human fibrinogen (SIGMA), 25 μl of 25 NIH/ E/ml human thrombin (SIGMA) and 40 μl of 100 mM CaCI 2 solution is placed and the mixtures are allowed to stand for 1 hour at 20-22 °C. The fibrin clots are washed with isotonic NaCI-solution (3x2 ml) under gentle stirring to remove traces of thrombin and sedimented for 5 min. The effectiveness of the washing can be checked by the method M1/c. Method M5 Determination of inhibition of fibrin-clot bound thrombin a) 0.1 - 1.0 - 10 and 100 μg/ml solutions are made from the peptide inhibitors with Hepes/NaCI buffer (0.001 M Hepes and 0.1M NaCl, pH=7.4). b) Measurements are continued according to M3/b. Method M6 Determination of factor Xa inhibition in solution on a 96-well microtitre plate a) By means of phosphate buffer (0.1M sodium phosphate and 0.05M sodium chloride, pH = 7.4) 1.3 E/ml solution is prepared from human factor Xa (SIGMA), and 0.1 - 1.0 - 1 0 and 100 μg/ml solutions from the peptide inh ibitors. The Bz-l le-Glu-Gly-Arg-pNA substrate is used in distilled water sol ution (0.33 nM) . b) From the control and the peptide inhibitor solutions (3 parallel samples of each concentration) 30-30 μl aliquots are placed into the wel l s. 30 μl of factor Xa, 90 μl of buf¬ fer and 1 50 μl of substrate are added to the peptide solu¬ tion and the extinction is determined after 10 min. at 405 nm . Thereafter the steps are the same as i n M2/c.

Claims: What we claim is: 1. New peptidyl-arginine aldehyde derivatives of general formula (I), Q-D-Xaa-Pro-Arg-H (I) wherein Q represents an acyl group of formula Q'-O-CO-, wherein Q' represents an alkyl-group with 1-3 carbon atoms, D-Xaa represents a 3-cyclobutyl-D-alanyl- or 3-cyclopentyl-D-alanyl group, Pro stands for an L-prolyl group, and Arg stands for an L-arginyl group, and their acid-addition salts formed with an organic or inorganic acid. 2. Ethoxycarbony l-3-cyclobuty I -D-al any I -L-proly l-L- arginine aldehyde and acid-addition salts thereof. 3. Methoxycarbonyl-3-cyclobutyl-D-alanyl-L-prolyl-L- arginine aldehyde and acid-addition salts thereof. 4. Ethoxycarbonyl-3-cyclopentyl-D-alanyl-L-prolyl-L- arginine aldehyde and acid-addition salts thereof. 5. Methoxy carbony l-3-cycl ope nty I -D-al any I -L-proly I- L-arginine aldehyde and acid-addition salts thereof. 6. A pharmaceutical composition which comprises as active ingredient at least one compound of formula (I), where the meaning of Q, D-Xaa, Pro and Arg are as de¬ fined in claim 1, or a pharmaceutically acceptable acid- addition salt thereof in admixture with carriers and/or additives commonly used in the pharmaceutical industry. 7. Compounds of general formula (I), where the meaning of Q, D-Xaa, Pro and Arg is as defined in claim 1, for use as a medicine. 8. Compounds of general formula (I), where the meaning of Q, D-Xaa, Pro and Arg is as defined in claim 1, for application as medicines in curing and preventing thrombosis and/or accelerated blood clotting.

Inventors: BAJUSZ SANDOR, BARABAS EVA, FEHER ANDRAS, JUHASZ ATTILA, KASZAS EVA, LANGO JOZSEF, LAVICH EMILIA, MAKK KLARA, MOHAI ZSUZSANNA, MORAVCSIK IMRE, SZABO GABRIELLA, SZALKAY ANNA MARIA, SZEKER AGNES, SZELL ERZSEBET, TASCHLER ZSUZSANNA, TOTH GABOR, VEGHELYI IREN, BAJUSZ, SANDOR, BARABAS, EVA, FEHER, ANDRAS, JUHASZ, ATTILA, KASZAS, EVA, LANGO, JOZSEF, LAVICH, EMILIA, MAKK, KLARA, MOHAI, ZSUZSANNA, MORAVCSIK, IMRE, SZABO, GABRIELLA, SZALKAY, ANNA MARIA, SZEKER, AGNES, SZELL, ERZSEBET, TASCHLER, ZSUZSANNA, TOTH, GABOR, VEGHELYI, IREN
Applicants: BAJUSZ SANDOR, BARABAS EVA, FEHER ANDRAS, GYOGYSZERKUTATO INTEZET, JUHASZ ATTILA, KASZAS EVA, LANGO JOZSEF, LAVICH EMILIA, MAKK KLARA, MOHAI ZSUZSANNA, MORAVCSIK IMRE, SZABO GABRIELLA, SZALKAY ANNA MARIA, SZEKER AGNES, SZELL ERZSEBET, TASCHLER ZSUZSANNA, TOTH GABOR, VEGHELYI IREN, BAJUSZ, SANDOR, BARABAS, EVA, FEHER, ANDRAS, GYOGYSZERKUTATO INTEZET KFT., JUHASZ, ATTILA, KASZAS, EVA, LANGO, JOZSEF, LAVICH, EMILIA, MAKK, KLARA, MOHAI, ZSUZSANNA, MORAVCSIK, IMRE, SZABO, GABRIELLA, SZALKAY, ANNA MARIA, SZEKER, AGNES, SZELL, ERZSEBET, TASCHLER, ZSUZSANNA, TOTH, GABOR, VEGHELYI, IREN
Application year: 1997
Main classification: C07K5
IPC codes: A61K31, A61K38, A61P7, C07K5